InSure® Colorectal Cancer Screening Test: Better at Detection of Early Stage Colorectal Cancers Compared to Traditional Test, New Study Says
November 3, 2006 by Gloria Gamat
Filed under Diseases & Conditions
Quest Diagnostics Incorporated (NYSE: DGX)’s Fecal Immunochemical Test (FIT) – InSure® – has been found to be able to detect three times as many early-stage colorectal cancers and nearly two times as many significant (pre- cancerous) adenomas compared to Hemoccult II Sensa® (1), the traditional guaiac fecal occult blood test.(2)
Such were the findings of a new study recently published in the journal Cancer.
InSure® FIT is a test that uses anti-human hemoglobin antibodies that are highly specific to human globin. Human globin is the primary protein in blood that is released in stool when cancer and significant pre-cancerous adenomas are present in the colon and rectum.
The InSure FIT demonstrated a true-positive result significantly more often in the presence of cancer (n=24, 87.5% vs. 54.2%) or significant adenoma (n=61, 42.6% vs. 23.0%) than did Hemoccult II Sensa.
Find more details of the said clinical data from the press release.
(1) Hemoccult II Sensa is a trademark of Beckman Coulter, Inc.
(2) Smith, A., Young, G. et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006; 107 (9) 2152-59.
